HansLeeMD

PubMed

• Impact of body mass index on outcomes of multiple myeloma patients undergoing upfront autologous stem cell transplant.
  Curtis Marcoux, Sarah Pasyar, Denái R Milton, Hina N Khan, Mark R Tanner
  British Journal of Haematology. 2024-11-28
• Impact of lenalidomide-bortezomib-dexamethasone induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect® MM Registry.
  Sikander Ailawadhi, Hans C Lee, James Omel, Kathleen Toomey, James W Hardin
  Blood Cancer Journal. 2024-11-11
• Characteristics and Treatment Patterns of Long-surviving Patients With Multiple Myeloma: Over 13 Years of Follow-up in the ConnectMM Registry.
  Howard R Terebelo, James Omel, Lynne I Wagner, James W Hardin, Robert M Rifkin
  Clinical Lymphoma, Myeloma & Leukemia. 2024-11-06

Journal Articles

• Primary Plasma Cell Leukemia: Autologous Stem Cell Transplant in an Era of Novel Induction Drugs  
  Krina Patel, Rohtesh Mehta, Donna M Weber, Sheeba K Thomas, Nina Shah, Hans C Lee, Elisabet E Manasanch, Muzaffar H Qazilbash, Qaiser Bashir, Simrit Parmar, Robert Z O..., Nature
• Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191  
  Sheeba K Thomas, Robert Z Orlowski, Hans C Lee, Clinical Cancer Research

Abstracts/Posters

• A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM)
  Hans C. Lee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM)
  Hans C. Lee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase 1/2 Study to Assess Safety and Dose of Ixazomib in Combination with Cyclophosphamide and Dexamethasone in Newly Diagnosed Patients with Light Chain (AL) Amyloi...
  Hans C. Lee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Outcomes of Lenalidomide Retreatment with Novel Triplet Regimens in Multiple Myeloma Patients Progressing on Lenalidomide-Based Maintenance Therapy: A Single Center Re...
  Hans C. Lee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Clinical Outcomes and Health-Related Quality of Life (HRQoL) Among Randomized Clinical Trial (RCT)-Eligible and RCT-Ineligible Patients: Results from the Connect¬ MM R...
  Hans C. Lee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IR...
  Hans C. Lee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Real-World (RW) Multiple Myeloma (MM) Patients (Pts) Remain Under-Represented in Clinical Trials Based on Standard Laboratory Parameters and Baseline Characteristics: ...
  Hans C. Lee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• A 3D Learning Experience: Novel Combination Treatment Options and Sequencing Strategies for Personalized Management of Relapsed and/or Refractory Multiple Myeloma 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Treatment Patterns and Outcomes in Elderly Patients with Newly Diagnosed Multiple Myeloma: Results from the Connect¬ MM Registry 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019